Previous 10 | Next 10 |
home / stock / aplif / aplif news
Company to provide update on drug development pipeline including recently announced US Department of Defense funding for biodefense vaccine candidate ATI-1701 Presentation scheduled for 2:30 pm ET on Thursday, March 10, 2022 HALIFAX, Nova Scotia, March 09, 2022 (GL...
NEW YORK, March 08, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Investor Forum on March 10 th . This virtual event will showcase live company presentations and intera...
Appili Therapeutics (OTCQX:APLIF) will get $10M funding from the U.S. Department of Defense (DOD) to advance its biodefense vaccine candidate ATI-1701 to prevent infection with Francisella tularensis, a type of aerobic bacteria and the causative agent of tularemia. The company said ...
Funds to advance ATI-1701 to IND submission Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that the U.S. Departme...
Appili Therapeutics press release (OTCQX:APLIF): FQ3 GAAP EPS of -C$0.05. Revenue of C$1.4M (+4566.7% Y/Y). For further details see: Appili Therapeutics GAAP EPS of -C$0.05, revenue of C$1.4M
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced its financial and operational results for the third quarter of its fiscal year 202...
Agreement expanded to add European and Latin American markets NDA filing with US FDA for Appili’s ATI-1501 expected later this year Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmac...
Positive one year challenge data builds on previously reported efficacy observed at 28- and 90-day challenge timepoints Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug deve...
Appili Therapeutics (OTCQX:APLIF): 1H GAAP EPS of -$0.30. As of September 30, 2021, the Company had cash and short-term investments of $10.0 million, compared to $16.1 million on March 31, 2021. Press Release For further details see: Appili Therapeutics reports 1H results
Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the second quarter of its fiscal year 2022, which e...
News, Short Squeeze, Breakout and More Instantly...
Appili Therapeutics Inc Company Name:
APLIF Stock Symbol:
OTCMKTS Market:
Appili Therapeutics Inc Website:
Appili, with a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets. Subject to the renewal of certain legislation, two programs are potentially eligible for FDA Priority Review Vouchers Aditxt, Inc. (...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 18, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...